Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study

Autor: FE Millard, Bercedis Peterson, Heli Collins, VL Brunetto, C Brabyn, Ivor Royston, R B Weiss, FR Davey, DB Duggan, RA Newman

Publikováno v: Blood. 82:1239-1246

The markers, CD11b, CD11c, CD14, CD21, CD23, CD25, CD38, and FMC7 were correlated with morphologic and other laboratory and clinical characteristics of 127 patients with untreated CD5+ chronic lymphocytic leukemia (CLL). Only CD38 and CD21 were signi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d17bdc18914d11c31d6bd9a7c569334
https://doi.org/10.1182/blood.v82.4.1239.1239

Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder.

Autor: Ramadas P; SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA.; LSU Health Sciences Center, 1501 Kings Hwy, Shreveport, LA 71103, USA., Williams M; SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA., Duggan DB; SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, USA.

Publikováno v: Case reports in hematology [Case Rep Hematol] 2021 Sep 27; Vol. 2021, pp. 4354941. Date of Electronic Publication: 2021 Sep 27 (Print Publication: 2021).

Every error a treasure: improving medication use with a nonpunitive reporting system.

Autor: Lehmann DF; Department of Medicine, State University of New York Upstate Medical Universtiy, Syracuse, New York, USA. lehmannd@upstate.edu, Page N, Kirschman K, Sedore A, Guharoy R, Medicis J, Ploutz-Snyder R, Weinstock RS, Duggan DB

Publikováno v: Joint Commission journal on quality and patient safety [Jt Comm J Qual Patient Saf] 2007 Jul; Vol. 33 (7), pp. 401-7.

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Autor: Parnes HL; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA. hp24c@nih.gov, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2003 May 01; Vol. 21 (9), pp. 1819-24.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Autor: Henderson IC; University of California at San Francisco, San, Francisco, CA 94143, USA. craig.henderson@accessoncology.com, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2003 Mar 15; Vol. 21 (6), pp. 976-83.